Neurocrine Biosciences (NASDAQ:NBIX) provides an update on its business operations during the COVID-19 pandemic.
The company continues to perform all activities
necessary to initiate a global registrational study of crinecerfont in
adult congenital adrenal hyperplasia (CAH) patients in mid-2020.
The commercial launch of opicapone is expected to be delayed until later this year.
Neurocrine is temporarily pausing enrollment of
new patients in the Phase III study of valbenazine for chorea in
Huntington disease, the RESTORE-1 registrational study for NBIb-1817 in
Parkinson’s disease and the Phase IIa pediatric study of crinecerfont in
CAH.
The company plans to have on-going studies in three registrational programs and five mid-stage programs by the end of 2020.
NBIX has donated supplies to San Diego area hospitals in response to COVID-19.
https://seekingalpha.com/news/3558168-neurocrine-bio-suspends-enrollment-in-key-study-amid-covidminus-19
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.